A number of firms have modified their ratings and price targets on shares of Gilead Sciences (NASDAQ: GILD) recently:

  • Gilead Sciences was upgraded by analysts at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating. They now have a $80.00 price target on the stock, up previously from $63.00.
  • Gilead Sciences had its “outperform” rating reaffirmed by analysts at Cowen.
  • Gilead Sciences had its price target raised by analysts at UBS AG from $65.00 to $80.00. They now have a “buy” rating on the stock.
  • Gilead Sciences had its “outperform” rating reaffirmed by analysts at Wells Fargo & Co..
  • Gilead Sciences was upgraded by analysts at Lazard Capital from a “neutral” rating to a “buy” rating. They now have a $89.00 price target on the stock.
  • Gilead Sciences had its price target raised by analysts at Maxim Group from $70.00 to $83.00. They now have a “buy” rating on the stock.
  • Gilead Sciences had its “outperform” rating reaffirmed by analysts at RBC Capital. They now have a $80.00 price target on the stock.

Shares of Gilead Sciences, Inc. traded up 1.43% during mid-day trading on Thursday, hitting $68.60. Gilead Sciences, Inc. has a 52 week low of $34.45 and a 52 week high of $70.39. The company has a market cap of $51.901 billion and a P/E ratio of 20.49.

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.